These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

97 related items for PubMed ID: 1514170

  • 1. Clearance of recombinant tissue factor pathway inhibitor (TFPI) in rabbits.
    Palmier MO, Hall LJ, Reisch CM, Baldwin MK, Wilson AG, Wun TC.
    Thromb Haemost; 1992 Jul 06; 68(1):33-6. PubMed ID: 1514170
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics of full length and two-domain tissue factor pathway inhibitor in combination with heparin in rabbits.
    Bregengaard C, Nordfang O, Ostergaard P, Petersen JG, Meyn G, Diness V, Svendsen O, Hedner U.
    Thromb Haemost; 1993 Sep 01; 70(3):454-7. PubMed ID: 8259548
    [Abstract] [Full Text] [Related]

  • 3. Recombinant full-length tissue factor pathway inhibitor (TFPI) prevents thrombus formation and rethrombosis after lysis in a rabbit model of jugular vein thrombosis.
    Kaiser B, Fareed J.
    Thromb Haemost; 1996 Oct 01; 76(4):615-20. PubMed ID: 8903005
    [Abstract] [Full Text] [Related]

  • 4. The carboxy terminus of tissue factor pathway inhibitor is required for interacting with hepatoma cells in vitro and in vivo.
    Warshawsky I, Bu G, Mast A, Saffitz JE, Broze GJ, Schwartz AL.
    J Clin Invest; 1995 Apr 01; 95(4):1773-81. PubMed ID: 7706485
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Enhancement of lipoprotein lipase activity by tissue factor pathway inhibitor.
    Mukherjee M, Kakkar VV.
    Thromb Haemost; 1999 Dec 01; 82(6):1648-51. PubMed ID: 10613650
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The effect of two-domain tissue factor pathway inhibitor on endotoxin-induced disseminated intravascular coagulation in rabbits.
    Bregengård C, Nordfang O, Wildgoose P, Svendsen O, Hedner U, Diness V.
    Blood Coagul Fibrinolysis; 1993 Oct 01; 4(5):699-706. PubMed ID: 8292719
    [Abstract] [Full Text] [Related]

  • 9. Distribution of the recombinant coagulation factor 125I-rFVIIa in rats.
    Beeby TL, Chasseaud LF, Taylor T, Thomsen MK.
    Thromb Haemost; 1993 Sep 01; 70(3):465-8. PubMed ID: 8259550
    [Abstract] [Full Text] [Related]

  • 10. Deranged blood coagulation equilibrium as a factor of massive liver necrosis following endotoxin administration in partially hepatectomized rats.
    Mochida S, Arai M, Ohno A, Yamanobe F, Ishikawa K, Matsui A, Maruyama I, Kato H, Fujiwara K.
    Hepatology; 1999 May 01; 29(5):1532-40. PubMed ID: 10216139
    [Abstract] [Full Text] [Related]

  • 11. Turnover of human extrinsic (tissue-type) plasminogen activator in rabbits.
    Korninger C, Stassen JM, Collen D.
    Thromb Haemost; 1981 Oct 01; 46(3):658-61. PubMed ID: 7198302
    [Abstract] [Full Text] [Related]

  • 12. Disposition characteristics of recombinant human interleukin-11 after a bolus intravenous administration in mice.
    Takagi A, Masuda H, Takakura Y, Hashida M.
    J Pharmacol Exp Ther; 1995 Nov 01; 275(2):537-43. PubMed ID: 7473136
    [Abstract] [Full Text] [Related]

  • 13. Plasma disappearance and organ distribution of recombinant human tumor necrosis factor-alpha in rats.
    Pang XP, Hershman JM, Pekary AE.
    Lymphokine Cytokine Res; 1991 Aug 01; 10(4):301-6. PubMed ID: 1932374
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Two receptor systems are involved in the plasma clearance of tissue factor pathway inhibitor in vivo.
    Narita M, Bu G, Olins GM, Higuchi DA, Herz J, Broze GJ, Schwartz AL.
    J Biol Chem; 1995 Oct 20; 270(42):24800-4. PubMed ID: 7559599
    [Abstract] [Full Text] [Related]

  • 17. Tissue distribution and depletion kinetics of bortezomib and bortezomib-related radioactivity in male rats after single and repeated intravenous injection of 14 C-bortezomib.
    Hemeryck A, Geerts R, Monbaliu J, Hassler S, Verhaeghe T, Diels L, Verluyten W, van Beijsterveldt L, Mamidi RN, Janssen C, De Coster R.
    Cancer Chemother Pharmacol; 2007 Nov 20; 60(6):777-87. PubMed ID: 17285316
    [Abstract] [Full Text] [Related]

  • 18. Disposition and metabolism of the new hypocholesterolemic compound S-8921 in rats and dogs.
    Yamaguchi T, Nakajima Y, Mizobuchi M, Inazawa K, Kanazu T, Kadono K, Ohkawa T, Iwatani K.
    Arzneimittelforschung; 1998 Oct 20; 48(10):995-1006. PubMed ID: 9825117
    [Abstract] [Full Text] [Related]

  • 19. Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor.
    Petersen LC, Sprecher CA, Foster DC, Blumberg H, Hamamoto T, Kisiel W.
    Biochemistry; 1996 Jan 09; 35(1):266-72. PubMed ID: 8555184
    [Abstract] [Full Text] [Related]

  • 20. Distribution of remikiren, a potent orally active inhibitor of human renin, in laboratory animals.
    Richter WF, Whitby BR, Chou RC.
    Xenobiotica; 1996 Mar 09; 26(3):243-54. PubMed ID: 8730917
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.